$ 95.82
Key Takeaways
Risk factor
Good trading liquidity
Profitability factor
Greatly overvalued vs peers
About
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of GKOS is 117 and suggests 22% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
